In Vivo Potency Assay for Adeno-Associated Virus-Based Gene Therapy Vectors Using AAVrh.10 as an Example

Human Gene Therapy Methods

Volumn 29, Issue 3, 2018, Pages 146-155

  De, Bishnu P ^a   Chen, Alvin ^a   Salami, Christiana O ^a   Van De Graaf, Benjamin ^a   Rosenberg, Jonathan B ^a   Pagovich, Odelya E ^a   Sondhi, Dolan ^a   Crystal, Ronald G ^a   Kaminsky, Stephen M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

AAV Vectors; Gene therapy; potency; quality control

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; DNA; MESSENGER RNA; RNA; RNA 18S;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DNA EXTRACTION; DNA VECTOR; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE THERAPY; IN VIVO STUDY; LIVER HOMOGENATE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; RNA VECTOR; ANIMAL; BAGG ALBINO MOUSE; DEPENDOPARVOVIRUS; GENE VECTOR; GENETICS; HUMAN; LIVER; METABOLISM; PROCEDURES; STANDARDS;

ANIMALS; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LIVER; MALE; MICE; MICE, INBRED BALB C; RNA, MESSENGER;

EID: 85048932212     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2017.246     Document Type: Article

References (35)

1. Food and Drug Administration. Guidance for Industry: Potency Tests for Cellular and Gene Therapy Products. https://www.fda.gov/downloads/ biologicsbloodvaccines/guidancecomplianceregulatory information/guidances/cellularandgenetherapy/ ucm243392.pdf (last accessed May 21, 2018).
2. Aalbers CJ, Bevaart L, Loiler S, et al. Preclinical potency and biodistribution studies of an AAV 5 vector expressing human interferonbeta (ART-I02) for local treatment of patients with rheumatoid arthritis. PLoS One 2015;10: e0130612.
3. Allay JA, Sleep S, Long S, et al. Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial. Hum Gene Ther 2011;22: 595-604.
4. Chulay JD, Ye GJ, Thomas DL, et al. Preclinical evaluation of a recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin made using a recombinant herpes simplex virus production method. Hum Gene Ther 2011;22:155-165.
5. Flotte TR, Zeitlin PL, Reynolds TC, et al. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum Gene Ther 2003;14:1079-1088.
6. Janson C, McPhee S, Bilaniuk L, et al. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther 2002;13:1391-1412.
7. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008;358:2240-2248.
8. Marks WJ, Jr., Bartus RT, Siffert J, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010;9:1164-1172.
9. McPhee SW, Janson CG, Li C, et al. Immune responses to AAV in a Phase I study for Canavan disease. J Gene Med 2006;8:577-588.
10. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011;365: 2357-2365.
11. Tardieu M, Zerah M, Husson B, et al. Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a Phase I/II trial. Hum Gene Ther 2014;25:506-516.
12. Worgall S, Sondhi D, Hackett NR, et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adenoassociated virus expressing CLN2 cDNA. Hum Gene Ther 2008;19:463-474.
13. Wright JF. Manufacturing and characterizing AAV-based vectors for use in clinical studies. Gene Ther 2008;15:840-848.
14. Chao H, Liu Y, Rabinowitz J, et al. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther 2000;2:619-623.
15. Ellis BL, Hirsch ML, Barker JC, et al. A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype. Virol J 2013;10:74.
16. Scallan CD, Lillicrap D, Jiang H, et al. Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector. Blood 2003;102:2031-2037.
17. Davidoff AM, Gray JT, Ng CY, et al. Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol Ther 2005;11:875-888.
18. Grimm D, Pandey K, Nakai H, et al. Liver transduction with recombinant adeno-associated virus is primarily restricted by capsid serotype not vector genotype. J Virol 2006;80: 426-439.
19. Hu C, Busuttil RW, Lipshutz GS. RH10 provides superior transgene expression in mice when compared with natural AAV serotypes for neonatal gene therapy. J Gene Med 2010;12:766-778.
20. Nathwani AC, Cochrane M, McIntosh J, et al. Enhancing transduction of the liver by adenoassociated viral vectors. Gene Ther 2009;16: 60-69.
21. Sands MS. AAV-mediated liver-directed gene therapy. Methods Mol Biol 2011;807:141-157.
22. Vance MA, Mitchell A, Samulski RJ. AAV biology, infectivity and therapeutic use from bench to Clinic. In: Hashad D, ed. Gene Therapy-Principles and Challenges. Rijeka, Croatia: InTech, 2015:119-143.
23. Zincarelli C, Soltys S, Rengo G, et al. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther 2008;16:1073-1080.
24. Davidoff AM, Ng CY, Zhou J, et al. Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. Blood 2003;102:480-488.
25. De BP, Heguy A, Hackett NR, et al. High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses. Mol Ther 2006;13:67-76.
26. Inagaki K, Fuess S, Storm TA, et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 2006;14:45-53.
27. Nietupski JB, Hurlbut GD, Ziegler RJ, et al. Systemic administration of AAV8-alpha-galactosidase A induces humoral tolerance in nonhuman primates despite low hepatic expression. Mol Ther 2011;19:1999-2011.
28. Wang G, Young SP, Bali D, et al. Assessment of toxicity and biodistribution of recombinant AAV8 vector-mediated immunomodulatory gene therapy in mice with Pompe disease. Mol Ther Methods Clin Dev 2014;1:14018.
29. Wu Z, Sun J, Zhang T, et al. Optimization of selfcomplementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther 2008; 16:280-289.
30. Locke ME, Milojevic M, Eitutis ST, et al. Genomic copy number variation in Mus musculus. BMC Genomics 2015;16:497.
31. Majidzadeh AK, Esmaeili R, Abdoli N. TFRC and ACTB as the best reference genes to quantify Urokinase Plasminogen Activator in breast cancer. BMC Res Notes 2011;4:215.
32. Banda M, Bommineni A, Thomas RA, et al. Evaluation and validation of housekeeping genes in response to ionizing radiation and chemical exposure for normalizing RNA expression in real-time PCR. Mutat Res 2008;649: 126-134.
33. Grace MB, McLeland CB, Gagliardi SJ, et al. Development and assessment of a quantitative reverse transcription-PCR assay for simultaneous measurement of four amplicons. Clin Chem 2003; 49:1467-1475.
34. Kuchipudi SV, Tellabati M, Nelli RK, et al. 18S rRNA is a reliable normalisation gene for real time PCR based on influenza virus infected cells. Virol J 2012;9:230.
35. Sondhi D, Peterson DA, Giannaris EL, et al. AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL. Gene Ther 2005;12:1618-1632.